ArticleAnnals of hematology2018

High chymotrypsin-like activity in the plasma of patients with newly diagnosed multiple myeloma treated with bortezomib is predictive of a better response and longer PFS.

Wioletta Romaniuk et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.